Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study

References

• Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–2181. doi:10.1056/NEJMra1406186.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Hematology Am Soc Hematol Educ Program. 2017;2017(1):470–479. doi:10.1182/asheducation-2017.1.470.
   PubMedGoogle Scholar
• Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476–102416. doi:10.1155/2015/102476.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Dueck AC, Scherber RM, et al. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm. 2015;2015:284706–284709. doi:10.1155/2015/284706.
   PubMed Web of Science ®Google Scholar
• Bak M, Jess T, Flachs EM, et al. Risk of inflammatory bowel disease in patients with chronic myeloproliferative neoplasms: a Danish nationwide cohort study. Cancers. 2020;12(9):2700. doi:10.3390/cancers12092700.
   PubMed Web of Science ®Google Scholar
• Bak M, Sørensen TL, Flachs EM, et al. Age-related macular degeneration in patients with chronic myeloproliferative neoplasms. JAMA Ophthalmol. 2017;135(8):835–843. doi:10.1001/jamaophthalmol.2017.2011.
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Szépligeti S, Bak M, et al. Vascular diseases in patients with chronic myeloproliferative Neoplasms–impact of comorbidity. Clin Epidemiol. 2019;11:955–967. doi:10.2147/CLEP.S216787.
   PubMed Web of Science ®Google Scholar
• Christensen AS, Møller JB, Hasselbalch HC. Chronic kidney disease in patients with the philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38(4):490–495. doi:10.1016/j.leukres.2014.01.014.
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515–6520. doi:10.1182/blood-2011-04-348755.
   PubMed Web of Science ®Google Scholar
• Landtblom AR, Bower H, Andersson TML, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203–2210. doi:10.1038/s41375-018-0027-y.
   PubMed Web of Science ®Google Scholar
• Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in philadelphia negative myeloproliferative neoplasms (MPN-K). a nested case-control study. Leukemia. 2019;33(8):1996–2005. doi:10.1038/s41375-019-0487-8.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96(10):1653–1665. doi:10.1007/s00277-017-3082-y.
   PubMed Web of Science ®Google Scholar
• Enblom A, Lindskog E, Hasselbalch H, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015;26(5):344–347. doi:10.1016/j.ejim.2015.03.009.
   PubMed Web of Science ®Google Scholar
• Bankar A, Zhao H, Iqbal J, et al. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leuk Lymphoma. 2020;61(8):1908–1919. doi:10.1080/10428194.2020.1749607.
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN landmark survey. BMC Cancer. 2016;16(1):167. doi:10.1186/s12885-016-2208-2.
   PubMedGoogle Scholar
• Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–408. doi:10.1182/blood-2011-01-328955.
   PubMed Web of Science ®Google Scholar
• Christensen SF, Svingel LS, Kjaersgaard A, et al. Healthcare resource utilization in patients with myeloproliferative neoplasms: a Danish nationwide matched cohort study. Eur J Haematol. 2022;109(5):526–541. doi:10.1111/ejh.13841.
   PubMed Web of Science ®Google Scholar
• Yu J, Parasuraman S, Paranagama D, et al. Impact of myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey. BMC Cancer. 2018;18(1):420. doi:10.1186/s12885-018-4322-9.
   PubMedGoogle Scholar
• Horsboel TA, Nielsen CV, Andersen NT, et al. Risk of disability pension for patients diagnosed with haematological malignancies: a register-based cohort study. Acta Oncol. 2014;53(6):724–734. doi:10.3109/0284186X.2013.875625.
   PubMed Web of Science ®Google Scholar
• Horsboel TA, Nielsen CV, Nielsen B, et al. Wage-subsidised employment as a result of permanently reduced work capacity in a nationwide cohort of patients diagnosed with haematological malignancies. Acta Oncol. 2015;54(5):743–749. doi:10.3109/0284186X.2014.999871.
   PubMed Web of Science ®Google Scholar
• Roaldsnes C, Holst R, Frederiksen H, et al. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017;98(1):85–93. doi:10.1111/ejh.12788.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Adelborg K, et al. The danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi:10.2147/CLEP.S179083.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22–25. doi:10.1177/1403494810387965.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-3.
   PubMed Web of Science ®Google Scholar
• Statistics Denmark [Internet]. Denmark: Statistics Denmark [cited 2023 Feb 20]. Available from: https://www.dst.dk/da/Statistik/emner/uddannelse-og-forskning/befolkningens-uddannelsesstatus/befolkningens-hoejst-fuldfoerte-uddannelse.
   Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, et al. The danish national patient registry: a review of content, data quality, and research potential. CLEP. 2015;7:449–490. doi:10.2147/CLEP.S91125.
   Google Scholar
• Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to assess charlson comorbidity index conditions in the population-based danish national registry of patients. BMC Med Res Methodol. 2011;11(1):83. doi:10.1186/1471-2288-11-83.
   PubMed Web of Science ®Google Scholar
• Bak M, Ibfelt EH, Stauffer Larsen T, et al. The Danish national chronic myeloid neoplasia registry. Clin Epidemiol. 2016;8:567–572. doi:10.2147/CLEP.S99462.
   PubMed Web of Science ®Google Scholar
• Hjollund NH, Larsen FB, Andersen JH. Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scand J Public Health. 2007;35(5):497–502. doi:10.1080/14034940701271882.
   PubMed Web of Science ®Google Scholar
• Arboe B, Olsen MH, Goerloev JS, et al. Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. Clin Epidemiol. 2017;9:321–329. doi:10.2147/CLEP.S134603.
   PubMed Web of Science ®Google Scholar
• De Barros S, Vayr F, Despas F, et al. The impact of chronic myeloid leukemia on employment: the french prospective study. Ann Hematol. 2019;98(3):615–623. doi:10.1007/s00277-018-3549-5.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139(19):2931–2941. doi:10.1182/blood.2021012743.
   PubMed Web of Science ®Google Scholar
• Stapelfeldt CM, Jensen C, Andersen NT, et al. Validation of sick leave measures: self-reported sick leave and sickness benefit data from a danish national register compared to multiple workplace-registered sick leave spells in a danish municipality. BMC Public Health. 2012;12(1):661. doi:10.1186/1471-2458-12-661.
   PubMed Web of Science ®Google Scholar
• Norgaard M, Skriver MV, Gregersen H, et al. The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry. Eur J Cancer Prev. 2005;14(3):201–206. doi:10.1097/00008469-200506000-00002.
   PubMed Web of Science ®Google Scholar